BioAge’s BGE-102 Delivers 85–87% hsCRP Cuts, Launching Mid-2026 Phase 2 Trial
BioAge’s Phase 1 trial of BGE-102 shows 85–87% median hsCRP reductions at 60 mg and 120 mg daily doses in obese participants over 14–21 days with favorable tolerability. Company plans a mid-2026 Phase 2 cardiovascular risk proof-of-concept trial and a Phase 1b/2a diabetic macular edema study by mid-2026.
1. Phase 1 Efficacy Results
The randomized, double-blind Phase 1 trial evaluated 60 mg and 120 mg once-daily doses of BGE-102 in obese participants with baseline hsCRP above 3 mg/L. Both cohorts achieved median hsCRP reductions of 85–87% over 14–21 days, with parallel IL-6 decreases (55–78%) and 19–30% fibrinogen reductions.
2. Safety and Tolerability
BGE-102 was well tolerated across all dose levels, with only mild to moderate treatment-emergent adverse events, no serious adverse events, no discontinuations for safety, and no clinically meaningful changes in vital signs, ECGs, or laboratory values.
3. Planned Development Program
Based on the full Phase 1 dataset, BioAge will initiate a Phase 2 dose-ranging cardiovascular risk proof-of-concept trial in the first half of 2026 with three oral doses and hsCRP as primary endpoint, followed by a Phase 1b/2a diabetic macular edema study in mid-2026, with data expected by late 2026 and mid-2027 respectively.